Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

Shares of NBRV stock opened at $0.00 on Friday. The company has a market cap of $9,604.50, a PE ratio of 0.00 and a beta of 1.53. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The firm’s fifty day simple moving average is $0.03.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.